# Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors

> **NCT06926751** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 132 (estimated)

## Conditions studied

- Solid Tumors
- Children
- Adolescent
- Chemotherapy Induced Neutropenia

## Interventions

- **DRUG:** Telpegfilgrastim Injection
- **DRUG:** filgrastim

## Key facts

- **NCT ID:** NCT06926751
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-12
- **Primary completion:** 2027-04-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06926751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06926751, "Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06926751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*